Area of interest
Dr. Jin has extensive experience and expertise in creating small molecule modulators of epigenetic targets including histone methyltransferases (HMTs). During the last 4.5 years, his lab has taken a target-class based approach to systematically creating chemical probes of HMTs and published 5 papers on discovering G9a/GLP inhibitors and chemical probes (Nature Chemical Biology (2011, 7, 566), Journal of Medicinal Chemistry (2009, 52, 7950; 2010, 53, 5844; and 2011, 54, 6139), and Chemistry & Biology (2010, 17, 695)). In particular, the Jin lab in collaboration with Dr. Cheryl Arrowsmith's lab at Structural Genomics Consortium discovered UNC0638, a chemical probe of G9a/GLP with high potency and selectivity, robust on-target activities in cells, and low cell toxicity (Nature Chemical Biology, 2011, 7, 566). To date, Dr. Jin has published 70 papers (including 48 papers since 2008). He is also an inventor of 8 issued U.S. patents and 38 PCT patent applications.
Prior to joining UNC in August 2008, Dr. Jin had > 10 years of experience in medicinal chemistry and drug discovery at GlaxoSmithKline (GSK), where he had most recently served as a Manager of Medicinal Chemistry from 2003 to 2008. Dr. Jin had led numerous multi-disciplinary small molecule drug discovery programs that successfully delivered numerous high quality leads and pre-candidates that led to multiple clinical candidates during his career at GSK.
Awards and Honors
- 1989 Huaxin Award, University of Science and Technology of China
- 1996 Bayer Award, The Pennsylvania State University
- 1998-2008 Silver & Bronze Recognition Awards, GlaxoSmithKline R&D